Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets

Journal of Chemical Information and Computer Sciences

Volumn 44, Issue 6, 2004, Pages 2157-2166

  Baurin, Nicolas ^a,b   Aboul Ela, Fareed ^a   Barril, Xavier ^a   Davis, Ben ^a   Drysdale, Martin ^a   Dymock, Brian ^a   Finch, Harry ^a   Fromont, Christophe ^a   Richardson, Christine ^a   Simmonite, Heather ^a   Hubbard, Roderick E ^a  

^a Vernalis PLC   (United Kingdom)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; CHARACTERIZATION; LIBRARIES; NUCLEAR MAGNETIC RESONANCE; PRODUCT DESIGN; PROTEINS; TARGETS;

BINDING SITES; FRAGMENT BINDING SITES; FRAGMENT LIBRARIES; PHARMACOPHORES;

MOLECULAR STRUCTURE;

PROTEIN;

ALGORITHM; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER PROGRAM; FACTUAL DATABASE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STRUCTURE ACTIVITY RELATION;

ALGORITHMS; DATABASES, FACTUAL; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; PROTEINS; SOFTWARE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 10044246303     PISSN: 00952338     EISSN: None     Source Type: Journal    
DOI: 10.1021/ci049806z     Document Type: Article

References (45)

1. Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering high affinity ligands for proteins: SAR by NMR. Science 1996, 274, 1531-1534.
2. Fejzo, J.; Lepre, C. A.; Peng, J. W.; Bemis, G. W.; Ajay; Murcko, M. A.; Moore, J. M. The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. Chem Biol. 1999, 10, 755-69.
3. Boehm, H. J.; Boehringer, M.; Bur, D.; Grauender, H.; Huber, W.; Klaus, W.; Kostrewa, D.; Kuehne, H.; Luebbers, T.; Meunier-Keller, N.; Mueller, F. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J. Med. Chem. 2000, 14, 2664-2674.
4. Nienaber, V. L.; Richardson, P. L.; Klighofer, V.; Bouska, J. J.; Giranda, V. L.; Greer, J. Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat. Biotechnol. 2000, 10, 1105-1108.
5. Sharff, A.; Jhoti, H. High Throughput crystallography to enhance drug discovery. Curr. Opin. Chem. Biol. 2003, 7, 340-345.
6. Erlanson, D. A.; McDowell, R. S.; O'Brien, T. Fragment-Based Drug Discovery. J. Med. Chem. 2004, 3463-3482.
7. Rees, D. C.; Congreve, M.; Murray, C. W.; Carr, R. Fragment-Based Lead Discovery. Nature Rev. Drug Discovery 2004, 3, 660-672.
8. Maly, D. J.; Choong, I. C.; Ellman, J. A. Combinatorial target-guided ligand assembly: Identification of potent subtype-selective c-Src inhibitors. PNAS 2000, 97, 2419-2424.
9. Lesuisse, D.; Lange, G.; Deprez, P.; Benard, D.; Schoot, B.; Delettre, G.; Marquette, J. P.; Broto, P.; Jean-Baptiste, V.; Eichet, P.; Sarubbi, E.; Mandine, E. SAR and X-ray. A new approach combining fragmentbased screening and rational drug design: application to the discovery of nanomolar inhibitors of Src SH2. J. Med. Chem. 2002, 45, 2379-2387.
10. Sanders, W. J.; Nienaber, V. L.; Lerner, C. G.; McCall, J. O.; Merrick, S. M.; Swanson, S. J.; Harlan, J. E.; Stoll, V. S.; Stamper, G. F.; Setz, S. F.; Condroski, K. R.; Meadows, R. P.; Severin, J. M.; Walter, K. A.; Magdalinos, P.; Jakob, C. G.; Wagner, R.; Beutel, B. A. Discovery of potent inhibitors of dihydroneptin aldolase using CrystaLEAD high-throughput crystallographic screening and structure-directed lead optimization. J. Med. Chem. 47, 1709-1718.
11. Pellecchia, M.; Sem, D. S.; Wuthrich, K. NMR in drug discovery. Nat. Rev. Drug Discovery 2002 1, 211-219.
12. Coles, M.; Heller, M.; Kessler, H. NMR-based screening technologies. Drug Discovery Today 2003, 8, 803-810.
13. Fejzo, J.; Lepre, C.; Xialoling, X. Application of NMR screening in Drug Discovery. Curr. Top. Med. Chem. 2003, 3, 81-97.
14. Jacoby, E.; Davies, J.; Blommers, M. J. Design of small molecule libraries for NMR screening and other applications in drug discovery. Curr. Top. Med. Chem. 2003, 3, 11-23.
15. Meyer, B.; Peters, T. NMR spectroscopic techniques for screening and identifying ligand binding to protein receptors. Angew, Chem. Int. Ed. 2003, 42, 864-890.
16. Mayer, M.; Meyer, B. Characterization of Ligand Binding by Saturation Transfer Difference NMR Spectra. Angew. Chem. Int. Ed. 1999, 35, 1784-1788.
17. Dalvit, C.; Pevarello, P.; Tato, M.; Veronesi, M.; Vulpetti, A.; Sundstrom, M. Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. J. Biomol, NMR 2000, 18, 65-68.
18. MDL Information Systems, Inc., 14600 Catalina Street, San Leandro, CA 94577, U.S.A. http://www.mdl.com.
19. Baurin, N.; Baker, R.; Richardson, C.; Chen, I.; Foloppe, N.; Potter, A.; Jordan, A.; Roughley, S.; Parratt, M.; Greaney, P.; Morley, D.; Hubbard, R. E. Drug-like annotation and duplicate analysis of a 23supplier chemical database totalling 2.7 million compounds. J. Chem. Inf. Comput. Sci. 2004, 44, 643-651.
20. Thomson Scientific, 3501 Market Street, Philadelphia, PA 19104, U.S.A., http://thomsonderwent.com/products/lr/wdi/.
21. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
22. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.
23. Huuskonen, J.; Rantanen, J.; Livingstone, D. Prediction of aqueous solubility for a diverse set of organic compounds based on atom-type electrotopological state indices. Eur. J. Med. Chem. 2000, 35, 1081-1088.s
24. Myrdal, P. B.; Manka, A. M.; Yalkowsky, S. H. AQUADAC 3: Aqueous Functional Group Activity Coefficients: Application to the estimation of aqueous solubility. Chemosphere 1995, 30, 1619-1637.
25. Muegge, I.; Heald, S. L.; Brittelli, D. Simple selection Criteria for Drug.like-like Chemical Matter. J. Med. Chem. 2001, 44, 1841-1846.
26. Bemis, G. W.; Murcko, M. A. The properties of Known Drugs. 1. Molecular Frameworks. J. Med. Chem. 1996, 39, 2887-2893.
27. Bemis, G. W.; Murcko, M. A. The properties of Known Drugs. 2. Side Chains. J. Med. Chem. 1999, 42, 5095-5099.
28. Hann, M. M.; Leach, A. R.; Harper G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 2001, 41, 856-864.
29. Chemical Computing Group Inc., Montreal, H3A 2R7 Canada, http:// www.chemcomp.com.
30. Makara, G. M. Measuring molecular similarity and diversity: total pharmacophore diversity. J. Med. Chem. 2001, 44, 3563-3571.
31. Reynolds, C. H.; Druker, R.; Pfahler, L. B. Lead Discovery Using Stochastic Cluster Analysis (SCA): A New Method for Clustering Structurally Similar Compounds. J. Chem. Inf. Comput. Sci. 1998; 38, 305-312.
32. Hwang, T. L.; Shaka, A. J. Multiple-pulse mixing sequences that selectively enhance chemical exchange or cross-relaxation peaks in high-resolution NMR spectra. J. Magn. Reson. 1998, 135, 280-287.
33. Accelrys Inc. 9685 Scranton Road. San Diego, CA 92121-3752, U.S.A. http://www.accelrys.com.
34. Wright, L.; Barril, X.; Dymock, B.; Sheridan, L.; Surgenor, A.; Beswick, M.; Drysdale, M.; Collier, A.; Massey, A.; Davies, N.; Fink, A.; Fromont, C.; Aherne, W.; Boxall, K.; Sharp, S.; Workman, P.; Hubbard, R. E. Structure-Activity Relationships in purine-based inhibitor binding to HSP90 isoforms. Chem. Biol. 2004, in press.
35. Chiosis, G.; Timaul, M. N.; Lucas, B.; Munster, P. N.; Zheng, F. F.; Sepp-Lorenzino, L.; Rosen, N. A small molecule designed to bind to the adenine nucleotide pocket of HSP90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. 2001, 8, 289-299.
36. Brown, N. R.; Noble, M. E. M.; Lawrie, A. M.; Morris, M. C.; Tunnah, P.; Divita, G.; Johnson, L. N.; Endicott, J. A. Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity. J. Biol. Chem. 1999, 274, 8746-8756.
37. De Azevedo, W. F.; Leclerc, S.; Meijer, L.; Havlicek, L.; Strnad, M.; Kim, S. H. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 1997, 243, 518-526.
38. Furet, P.; Meyer, T.; Strauss, A.; Raccuglia, S.; Rondeau, J.-M. Structure-Based Design and Protein X-ray Analysis of a Protein Kinase Inhibitor. Bioorg. Med. Chem. Lett. 2002, 12, 221-224.
39. Meijer, L.; Thunnissen, A. M.; White, A. W.; Gamier, M.; Nikolic, M.; Tsai, L. H.; Walter, J.; Cleverley, K. E.; Salinas, P. C.; Wu, Y. Z.; Biernat, J.; Mandelkow, E. M.; Kim, S. H.; Pettit, G. R. Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol. 2000, 7, 51-63.
40. Stahura, F. L.; Xue, L.; Godden, J. W.; Bajorath, J. Molecular scaffold-based design and comparison of combinatorial libraries focused on the ATP-binding site of protein kinases. J. Mol. Graph Model 1999, 19, 1-9.
41. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A. A 'rule of three' for fragment-based lead discovery? Drug Discovery Today 2003, 8, 876-877.
42. Lepre, C. A. Library design for NMR-based screening. Drug Discovery Today 2001, 6, 133-140.
43. English, A. C.; Groom, C. R.; Hubbard, R. E. Experimental and computational mapping of the binding surface of a crystalline protein. Prot. Eng. 2001, 14, 47-59.
44. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. J. Med. Chem. 2002, 45, 2615-2623.
45. Takaoka, Y.; Endo, Y.; Yamanobe, S.; Kakinuma, H.; Okubo, T.; Shimazaki, Y.; Ota, T.; Sumiya, S.; Yoshikawa, K. Development of a Method for Evaluating Drug-Likeness and Ease of Synthesis Using a Data Set in Which Compounds Are Assigned Scores Based on Chemists' Intuition. J. Chem. Inf. Comput. Sci. 2003, 43, 1269-1275.